Matt Paulson
About Matt Paulson
Matt Paulson serves as the Vice President of Development Operations and Systems at CytomX Therapeutics, where he has worked since 2022. He has extensive experience in translational research, project management, and strategic planning within the biotechnology and pharmaceutical sectors.
Work at CytomX Therapeutics
Matt Paulson serves as the Vice President of Development Operations and Systems at CytomX Therapeutics. He has held this position since 2022 and is based in South San Francisco, California. In this role, he is responsible for overseeing development operations and systems, contributing to the advancement of the company's therapeutic programs.
Education and Expertise
Matt Paulson has an extensive educational background. He earned a Bachelor of Arts in Biology from Harvard University, followed by a Ph.D. in Immunology and Oncology from NYU School of Medicine, Sackler Institute of Graduate Biomedical Sciences. Additionally, he completed an MBA in Operations and Finance at Golden Gate University. His education equips him with a strong foundation in both scientific research and business management.
Background
Before joining CytomX Therapeutics, Matt Paulson held various significant positions in the biotechnology and pharmaceutical sectors. He worked as an Executive Director at Iovance Biotherapeutics from 2016 to 2019 and as a Senior Director at Assembly Biosciences, Inc. from 2015 to 2016. His earlier experience includes a decade at Gilead Sciences as Associate Director of Project and Portfolio Management and a postdoctoral role at The Rockefeller University.
Achievements
Throughout his career, Matt Paulson has managed translational research projects, including pharmacogenomics and biomarker studies. He has led cross-functional teams focused on commercialization and has collaborated with the FDA and Key Opinion Leaders on various submissions and publication strategies. His experience spans all phases of clinical development, including pre-clinical to Phase 3, in areas such as cellular therapy and biologics.